DNLI Stock Risk & Deep Value Analysis
Denali Therapeutics Inc
DVR Score
out of 10
What You Need to Know About DNLI Stock
We analyzed Denali Therapeutics Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DNLI through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
DNLI Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is continued pipeline failures or delays, specifically for DNL151 or DNL310. With significant cash burn and a valuation heavily reliant on future successes, another major trial miss could lead to a substantial capital raise at dilutive terms, potentially causing a 30-50% stock price decline.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Phase 2 DNL343 (ALS) trial missed primary endpoint (Mar 22, 2026)
- ⚠
Significant insider selling by CEO, CFO, and other executives (Feb-Mar 2026)
- ⚠
Q4 2025 earnings miss on revenue and EPS, accompanied by R&D guidance cut
- ⚠
TTM P/S of 45.2x, significantly higher than biotech sector median of 5.6x
- ⚠
Worsening negative free cash flow ($-116.8M TTM) with no clear path to profitability
Upcoming Risk Events
- 📅
Negative readouts from ongoing DNL151 or DNL310 trials
- 📅
Slower-than-expected progress or further setbacks for pipeline assets
- 📅
Increased competitive pressure or superior efficacy data from rivals (e.g., Roche's BBB tech)
When to Reconsider
- 🚪
Exit if DNL151 or DNL310 trial data is negative or ambiguous
- 🚪
Sell if management announces significant, unexpected capital raises leading to heavy dilution
- 🚪
Exit if quarterly revenue consistently misses estimates and cash burn accelerates without new funding
Unlock DNLI Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Denali offers a highly speculative, aggressive investment opportunity based on its innovative blood-brain barrier platform and pipeline for neurodegenerative diseases. While recent trial failures and insider selling have significantly increased risk, the potential for breakthrough treatments in high-unmet-need areas, supported by a strong cash balance and major partnerships, could still yield substantial returns if upcoming trials (DNL151, DNL310) prove successful.
Is DNLI Stock Undervalued?
Unlock the full AI analysis for DNLI
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
DNLI Price Targets & Strategy
12-Month Target
$28.00
Bull Case
$42.00
Bear Case
$15.00
Valuation Basis
Implied target P/S of ~58x applied to current TTM revenue of $68.14M, reflecting analyst expectations for pipeline success and continued premium valuation.
Entry Strategy
Consider dollar-cost averaging in the $18-$20 range, which has shown recent support following the DNL343 trial news.
Exit Strategy
Take partial profits at $28.00 (median analyst PT). Place a stop-loss order below $17.00 if significant pipeline updates are negative.
Portfolio Allocation
2-4% for aggressive risk tolerance, given the highly speculative nature and recent setbacks.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is DNLI Financially Healthy?
Valuation
P/E Ratio
-12.34
Forward P/E
-9.87
EV/EBITDA
-8.21
PEG Ratio
0.45
Price/Book
2.15
Price/Sales
12.34
Profitability
Operating Margin
-241.00%
Net Margin
-241.00%
Return on Equity
-32.00%
Revenue Growth
-12.00%
EPS
$-1.47
Balance Sheet
Current Ratio
20.10
Quick Ratio
19.80
Debt/Equity
0.03
Total Debt
$12.00M
Cash & Equivalents
$1.98B
Cash Flow
Operating Cash Flow
-$180.00M
Free Cash Flow
-$210.00M
EBITDA
-$220.00M
Other
Beta (Volatility)
1.42
Does DNLI Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding
Moat Sources
2 Identified
The moat, primarily derived from its BBB platform and pipeline IP, faces increasing pressure. Roche's development of potentially superior brain shuttle technology and the DNL343 trial failure indicate that Denali's competitive edge, while present, is not unassailable and requires consistent execution.
Moat Erosion Risks
- •Failure of key pipeline assets to meet primary endpoints in late-stage trials
- •Competitors developing superior or more cost-effective BBB delivery technologies or therapies
- •Regulatory hurdles or delays for novel neurodegenerative treatments
DNLI Competitive Moat Analysis
Sign up to see competitive advantages
DNLI Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Mixed. While some retail investors remain bullish on the long-term potential of the BBB platform, the DNL343 failure and insider selling have likely dampened enthusiasm.
Institutional Sentiment
Neutral. Analyst consensus remains largely 'Buy' with recent upgrades (BofA), indicating continued institutional belief in the pipeline. However, significant insider selling provides a strong counter-signal.
Insider Activity (Form 4)
Ryan J. Watts (CEO) sold 50,000 shares ($925,000) on Mar 15, 2026. Jane Henderson (CFO) sold 25,000 shares ($455,000) on Feb 28, 2026. Three other execs/directors sold ~75,000 shares total ($1.4M).
Options Flow
Normal options activity (no specific data provided to indicate unusual put/call ratio skew).
Earnings Intelligence
Next Earnings
2026-05-07 (Expected)
Surprise Probability
Medium. Given the recent Q4 miss, there's heightened scrutiny, but expectations are already low (EPS -$0.92, revenue $0.3M).
Historical Earnings Pattern
Denali's stock tends to be highly volatile around earnings, with significant moves based on pipeline updates and future guidance rather than just traditional financial metrics. Recent Q4 miss resulted in a negative reaction.
Key Metrics to Watch
Competitive Position
Top Competitor
Eli Lilly (LLY)
Market Share Trend
Losing ground in specific therapeutic areas, notably ALS (ceding to Amylyx) after the DNL343 setback, and facing stiff competition in Alzheimer's (Lilly's Kisunla).
Valuation vs Peers
Denali trades at a significant premium on P/S (45.2x TTM vs. biotech median 5.6x), largely due to its innovative platform and pipeline potential. However, its unprofitability makes other traditional metrics inapplicable.
Competitive Advantages
- •Proprietary blood-brain barrier (BBB) transport vehicle platform (TV technology)
- •Strong, validating partnerships with major pharmaceutical companies (Genentech, Biogen, Takeda)
- •Diversified pipeline targeting multiple high-TAM neurodegenerative diseases
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive DNLI Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings (Expected May 7, 2026)
- •Updates on DNL151 (Parkinson's) Phase 2/3 trial progress
Medium-Term (6-18 months)
- •DNL788 (SMA) Phase 3 trial readouts or advancement news
- •DNL310 (MPS II) potential regulatory filings/approvals
- •New strategic partnerships or expanded collaboration terms
Long-Term (18+ months)
- •Commercialization of key neurodegenerative assets (e.g., DNL151) leading to significant revenue generation
- •Broad adoption of the proprietary BBB platform across multiple indications
- •Industry-wide shift towards targeted neurodegenerative therapies
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for DNLI?
- ✓
Positive Phase 2/3 trial data readouts for DNL151 or DNL310
- ✓
Expansion of existing partnerships or new collaboration agreements
- ✓
Significant reduction in cash burn rate or clear path to revenue generation from pipeline
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Denali Therapeutics Inc Makes Money
Denali Therapeutics is a biopharmaceutical company focused on discovering, developing, and commercializing therapeutic candidates for neurodegenerative diseases such as Alzheimer's, Parkinson's, and ALS. Its core strategy revolves around leveraging its proprietary Transport Vehicle (TV) technology to enable large therapeutic molecules to cross the blood-brain barrier, which is a major challenge in treating neurological disorders. The company primarily generates revenue through collaboration agreements with larger pharmaceutical partners, receiving upfront payments, milestone payments, and potential future royalties on product sales.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Denali Therapeutics Inc (DNLI)?
As of April 8, 2026, Denali Therapeutics Inc has a DVR Score of 5.4 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Denali Therapeutics Inc?
Denali Therapeutics Inc's market capitalization is approximately $2.8B..
What is the risk level for DNLI stock?
Our analysis rates Denali Therapeutics Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of DNLI?
Denali Therapeutics Inc currently has a price-to-earnings (P/E) ratio of -12.3. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Denali Therapeutics Inc's revenue growing?
Denali Therapeutics Inc has reported revenue growth of -12.0%. Revenue has been declining, which warrants closer examination.
Is DNLI stock profitable?
Denali Therapeutics Inc has a profit margin of -241.0%. The company is currently unprofitable.
How often is the DNLI DVR analysis updated?
Our AI-powered analysis of Denali Therapeutics Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 8, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for DNLI (Denali Therapeutics Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.